Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 7/20 | 0.40 |
| ▸ | CNR1 | P21554 | 5/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.36 |
| ▸ | CTSA | P10619 | 1/20 | 0.36 |
| ▸ | XIAP | P98170 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.35 |
| ▸ | KMO | O15229 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4088393 | 0.83 | MAPT (0.43) | CNR2CNR1 | |
| SCHEMBL4088395 | 0.83 | MAPT (0.43) | CNR2CNR1 | |
| SCHEMBL4943891 | 0.74 | NPC1 (0.42) | — | |
| SCHEMBL4093768 | 0.69 | NTRK1 (0.38) | CNR2NTRK1JAK2JAK3ABL1 | |
| SCHEMBL18014763 | 0.67 | ABL1 (0.41) | CNR2CNR1IRAK4KMOABL1 | |
| SCHEMBL2459503 | 0.63 | CPN1 (0.45) | — | |
| SCHEMBL12139742 | 0.63 | KMO (0.42) | CNR1SCN9ACTSAIRAK4KMO | |
| SCHEMBL2609333 | 0.63 | KMO (0.45) | KMOABL1 | |
| SCHEMBL12139880 | 0.62 | HSD17B14 (0.40) | CNR2CNR1SCN9ACTSAIRAK4 | |
| SCHEMBL25458067 | 0.62 | ALDH1A1 (0.45) | NTRK1SCN9AIRAK4ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203692-A1 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203692-A1 | NOVEL CHEMICAL COMPOUNDS | HIPK3, HIPK1, HIPK4 | CNR2 4806/4885CNR1 4788/4885NTRK1 3954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.